CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Efficacy and safety of ofatumumab and siponimod compared to fingolimod in pediatric patients with multiple sclerosis...
Phase 3
Roma, RM, Italy and 72 other locations
This extension study will evaluate the effectiveness and safety of ocrelizumab in multiple sclerosis (MS) participants who...
Phase 3
Roma, Lazio, Italy and 161 other locations
To evaluate the safety and efficacy of fingolimod vs. interferon beta-1a i.m. in pediatric patients with multiple sclerosis (MS...
Phase 3
Roma, RM, Italy and 107 other locations
with fingolimod in children and adolescents with relapsing-remitting multiple sclerosis aged between 10 and < 18 years over a durat...
Phase 3
Roma, Lazio, Italy and 118 other locations
study will compare ofatumumab vs. European approved platform first line self-administered disease modifying therapy (DMT) in newly diagnosed MS...
Phase 3
Roma, RM, Italy and 49 other locations
Open-label study to evaluate the effectiveness of treatment with ofatumumab in subjects transitioning from any fumarate-based RMS approved therapy or...
Phase 3
Roma, RM, Italy and 122 other locations
To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)...
Phase 3
Roma, RM, Italy and 208 other locations
The primary objectives are to investigate the safety and tolerability of BIIB091 monotherapy in participants with relapsing multiple sclerosis...
Phase 2
Roma, Italy and 70 other locations
The primary objective of Part 2 is to evaluate the long-term safety of BG00012 in subjects who completed Week 96 in Part 1 of Study 109MS306...
Phase 3
Rome, Italy and 61 other locations
and adolescents ages ≥ 10 to ≤ 18 years with relapsing-remitting multiple sclerosis (RRMS). The data from this study will serve to ...
Phase 2
Roma, Lazio, Italy and 11 other locations
Clinical trials
Research sites
Resources
Legal